President and CEO of SimBioSys
Appears in 1 story
Leading the company through the FDA clearance
The Food and Drug Administration cleared the first AI-powered tool that estimates breast cancer recurrence risk from an MRI a patient already has. SimBioSys's TumorSight Risk turns routine breast MRI, pathology, and clinical data into a five- and ten-year recurrence estimate, available before surgery.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
